# EDGAR Filing Document

**Accession Number:** 0001021561
**File Stem:** 0001140361-23-007254
**Filing Date:** 2023-2
**Character Count:** 35438
**Document Hash:** 6a02a0f1a414a39f8fdf6e3a6a21f25f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001140361-23-007254.hdr.sgml**: 20230215

**ACCESSION NUMBER**: 0001140361-23-007254

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20230215

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230215

**DATE AS OF CHANGE**: 20230215

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NU SKIN ENTERPRISES, INC.
- **CENTRAL INDEX KEY:** 0001021561
- **STANDARD INDUSTRIAL CLASSIFICATION:** WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122]
- **IRS NUMBER:** 870565309
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-12421
- **FILM NUMBER:** 23635602

**BUSINESS ADDRESS:**
- **STREET 1:** 75 WEST CENTER ST
- **STREET 2:** ATTN: GREGORY BELLISTON
- **CITY:** PROVO
- **STATE:** UT
- **ZIP:** 84601
- **BUSINESS PHONE:** 801-345-1000

**MAIL ADDRESS:**
- **STREET 1:** 75 WEST CENTER ST
- **STREET 2:** ATTN: GREGORY BELLISTON
- **CITY:** PROVO
- **STATE:** UT
- **ZIP:** 84601

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NU SKIN ENTERPRISES INC
- **DATE OF NAME CHANGE:** 19980909

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NU SKIN ASIA PACIFIC INC
- **DATE OF NAME CHANGE:** 19960919

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

### FORM 8-K

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

---

| |
|:---|
| **February 15, 2023**<br>|
| Date of Report (Date of earliest event reported) <br>|

---

---

| |
|:---|
| **NU SKIN ENTERPRISES, INC.**<br>|
| (Exact name of registrant as specified in its charter) <br>|

---

---

| | | |
|:---|:---|:---|
| **Delaware**<br>| **001-12421**<br>| **87-0565309**<br>|
| (State or other jurisdiction of incorporation) | (Commission File Number) <br>| (IRS Employer Identification Number) |

---

---

| |
|:---|
| **75 West Center Street**<br>**Provo, Utah 84601** |
| (Address of principal executive offices and zip code) <br>|

---

<u> (801) 345-1000 </u> <br> (Registrant's telephone number, including area code)

---

| |
|:---|
| **N/A** |
| (Former name or former address, if changed since last report) |

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Class A Common Stock, $.001 par value<br>| NUS<br>| New York Stock Exchange<br>|

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 2.02** | **Results of Operations and Financial Condition.** |

---

On February 15, 2023, Nu Skin Enterprises, Inc. (the "Company") issued a press release announcing its financial results for the three-month and annual periods ended December 31, 2022, and certain other information. A copy of the press release is attached as Exhibit 99.1 to this report.

The information furnished pursuant to this Item 2.02 and Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act except as shall be expressly set forth by specific reference in such filing.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.** |

---

&nbsp;&nbsp;&nbsp;&nbsp;(d) Exhibits.

[99.1](brhc10048304_ex99-1.htm) Nu Skin Enterprises' press release dated February 15, 2023, regarding financial results for the three-month and annual periods ended December 31, 2022. <br>104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

------

#### SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
|  | **NU SKIN ENTERPRISES, INC.**<br>(Registrant)<br>/s/ Mark H. Lawrence |
|  | Mark H. Lawrence |
|  | Chief Financial Officer |
| Date: February 15, 2023 |  |

---

------

## Exhibit 99.1

------

**Exhibit 99.1**<br>

![](image00001.jpg)

#### FOR IMMEDIATE RELEASE

#### Nu Skin Enterprises Reports Fourth Quarter and 2022 Financial Results

#### Company Provides Initial Outlook for Q1 and FY 2023

**PROVO, Utah — Feb. 15, 2023 —** Nu Skin Enterprises, Inc. (NYSE: NUS) today announced fourth quarter and full year 2022 results.

#### Executive Summary

#### Q4 2022 vs. Prior-year Quarter

---

| | |
|:---|:---|
| **Revenue:** | $522.3 million; (22)%<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•(7)% FX impact or $(51) million |
| **Earnings Per Share** <br> **(EPS):** | $1.15 or $0.89 excluding restructuring and impairment charges associated with the company's strategic resource reallocation and a recent IRS - approved favorable tax method change, compared to $(0.18) or $1.11 excluding restructuring and impairment charges in Q4 2021 |
| **Customers:** | 1,147,124; (16)% |
| **Paid Affiliates:** | 236,956; (13)% |
| **Sales Leaders:** | 48,737; (21)% |

---

#### Executive Summary

#### 2022 vs. 2021

---

| | |
|:---|:---|
| **Revenue:** | $2.23 billion; (17)%<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•(5)% FX impact or $(150) million |
| **Earnings Per Share** <br> **(EPS):** | $2.07 or $2.90 excluding restructuring and impairment charges and a tax method change, compared to $2.86 or $4.14 excluding restructuring and impairment charges |

---

"We made steady progress toward our Nu Vision 2025 strategy, despite persistent macro-economic challenges, which primarily included COVID-related disruptions in Mainland China, global inflation and foreign currency headwinds," said Ryan Napierski, Nu Skin president and CEO. "We achieved several key milestones during 2022 including the introduction of our first connected device, ageLOC® LumiSpa® iO, further strengthening our position as the world's leading beauty device system brand; the rollout of our Vera and Stela apps in all markets, which provide increased consumer and affiliate engagement; and steady advancements with our social commerce model. While we saw our sales channel contract primarily due to macroeconomic factors, we drove annual revenue growth of 4 percent in the U.S. and 2 percent in Southeast Asia/Pacific. Japan and Hong Kong/Taiwan also grew in constant currency, while reported revenue was down due to FX headwinds.

------

*Nu Skin Enterprises Reports Fourth Quarter and 2022 Financial Results* *page 2*

"Looking ahead, while the macro-environment remains uncertain, we expect it to steadily improve throughout the year. We remain confident in our Nu Vision 2025 strategy to help drive long-term growth and increase shareholder value, which we will update on our earnings call today. During the year, we will be advancing our EmpowerMe personalized beauty and wellness strategy by introducing our body iO smart, connected device system and rolling out our TRMe® weight management line. We will also continue to enhance our Vera and Stela apps with additional capabilities, features and improvements to streamline the overall user experience. In addition, as we continue to expand our affiliate-powered social commerce model, we will focus on stabilizing performance in more challenged regions and leveraging best practices from our markets that are further along in their social commerce transition. Lastly, as we navigate the year ahead, we will continue to be conservative in our guidance and prudent in our cost management while we invest in our future."

#### Q4 2022 Year-over-year Operating Results

#### <br>

---

| | |
|:---|:---|
| **Revenue:**  | $522.3 million compared to $673.4 million<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•(7)% FX impact or $(51) million |
| **Gross Margin:**  | 71.7% compared to 74.2% or 75.2% excluding restructuring and impairment charges in Q4 2021<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Impacted by geographic footprint, foreign currency and global inflationary pressures<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Nu Skin business was 74.9% compared to 77.9% |
| **Selling Expenses:**  | 38.5% compared to 39.1%<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Nu Skin business was 40.5% compared to 41.4% |
| **G&A Expenses:**  | 24.4% compared to 24.4% |
| **Operating Margin:**  | 5.3% or 8.8% excluding restructuring and impairment charges, compared to 3.0% or 11.7% excluding restructuring and impairment charges |
| **Other Income /** <br> **(Expense):** | $(3.1) million compared to $(1.9) million |
| **Income Tax Rate:** | (134.9)% or (3.7)% excluding restructuring and impairment charges and a recent IRS-approved favorable tax method change, compared to 150.1% or 26.9% excluding restructuring and impairment charges |
| **EPS:** | $1.15 or $0.89 excluding restructuring and impairment charges and a tax method change, compared to $(0.18) or $1.11 excluding restructuring and impairment charges |

---

------

*Nu Skin Enterprises Reports Fourth Quarter and 2022 Financial Results* *page 3*

#### Stockholder Value

#### <br>

---

| | |
|:---|:---|
| **Dividend Payments:** | $19.0 million |
| **Stock Repurchases:** | $10.0 million<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•$175.4 million remaining in authorization |

---

#### Q1 and Full-year 2023 Outlook

#### <br>

---

| | |
|:---|:---|
| **Q1 2023 Revenue:** | $450 to $490 million; (26) to (19)%<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Approximately (6) to (5)% FX impact |
| **Q1 2023 EPS:** | $0.17 to $0.27 or $0.25 to $0.35 non-GAAP |
| **2023 Revenue:** | $2.03 to $2.18 billion; (9)% to (2)%<br> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•Approximately (2) to (1)% FX impact |
| **2023 EPS:** | $2.27 to $2.67 or $2.35 to $2.75 non-GAAP |

---

"Our initial 2023 guidance assumes the global macro environment remains challenging in the near-term, improving throughout the year," said Mark Lawrence, chief financial officer. "Our annual revenue guidance is $2.03 to $2.18 billion, with an approximate 1 to 2 percent foreign currency headwind. We anticipate reported EPS of $2.27 to $2.67 or $2.35 to $2.75 excluding charges associated with a modest amount of 2023 restructuring. For the first quarter, we project revenue of $450 to $490 million, assuming a negative foreign currency impact of approximately 5 to 6 percent, with reported earnings per share of $0.17 to $0.27 or $0.25 to $0.35 when excluding an anticipated first-quarter restructuring and impairment charge of $5 to $10 million."

#### Conference Call
The Nu Skin Enterprises management team will host a conference call with the investment community today at 5 p.m. (ET). Those wishing to access the webcast, as well as the financial information presented during the call, can visit the Investor Relations page on the company's website at ir.nuskin.com. A replay of the webcast will be available on the same page through March 1, 2023.

------

*Nu Skin Enterprises Reports Fourth Quarter and 2022 Financial Results* *page 4*

#### About Nu Skin Enterprises, Inc.

***Important Information Regarding Forward-Looking Statements:** This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent the company's current expectations and beliefs. All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws and include, but are not limited to, statements of management's expectations regarding the macro-environment and the company's performance, growth, shareholder value, financial position, strategies, vision, transformation, initiatives, product pipeline and product introductions, digital and social-commerce tools and initiatives, customers, sales leaders, affiliates, and operational improvements; projections regarding revenue, expenses, operating income, earnings per share, foreign currency fluctuations, uses of cash and other financial items; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as "believe," "expect," "anticipate," "project," "continue," "outlook," "guidance," "remain," "become," "plan," "potential," "expand," "will," "would," "could," "may," "might," the negative of these words and other similar words.*

*The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:*

<br> • *risk that epidemics, including COVID-19 and related disruptions, and other crises could negatively impact our business;*

<br> • *adverse publicity related to the company's business, products, industry or any legal actions or complaints by the company's sales force or others;*

• *risk that direct selling laws and regulations in any of the company's markets, including the United States and Mainland China, may be modified, interpreted or enforced in a manner that results in negative changes to the company's business model or negatively impacts its revenue, sales force or business, including through the interruption of sales activities, loss of licenses, increased scrutiny of sales force actions, imposition of fines, or any other adverse actions or events;*

<br> • *any failure of current or planned initiatives or products to generate interest among the company's sales force and customers and generate sponsoring and selling activities on a sustained basis;*

<br> • *political, legal, tax and regulatory uncertainties, including trade policies, associated with operating in Mainland China and other international markets;*

<br> • *uncertainty regarding meeting restrictions and other government scrutiny in Mainland China, as well as negative media and consumer sentiment in Mainland China on our business operations and results;*

------

*Nu Skin Enterprises Reports Fourth Quarter and 2022 Financial Results* *page 5*

<br> • *risk of foreign-currency fluctuations and the currency translation impact on the company's business associated with these fluctuations;*

<br> • *uncertainties regarding the future financial performance of the businesses the company has acquired;*

• *risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support planned initiatives or launch strategies, and increased risk of inventory write-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies;*

• *regulatory risks associated with the company's products, which could require the company to modify its claims or inhibit its ability to import or continue selling a product in a market if the product is determined to be a medical device or if the company is unable to register the product in a timely manner under applicable regulatory requirements;*

<br> • *unpredictable economic conditions and events globally;*

• *the company's future tax-planning initiatives; any prospective or retrospective increases in duties or tariffs on the company's products imported into the company's markets outside of the United States; and any adverse results of tax audits or unfavorable changes to tax laws in the company's various markets; and*

<br> • *continued competitive pressures in the company's markets.*

*The company's financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company's beliefs as of the date that such information was first provided, and the company assumes no duty to update the forward-looking statements contained in this release to reflect any change except as required by law.*

***Non-GAAP Financial Measures:** Constant-currency revenue change is a non-GAAP financial measure that removes the impact of fluctuations in foreign-currency exchange rates, thereby facilitating period-to-period comparisons of the company's performance. It is calculated by translating the current period's revenue at the same average exchange rates in effect during the applicable prior-year period and then comparing that amount to the prior-year period's revenue. The company believes that constant-currency revenue change is useful to investors, lenders and analysts because such information enables them to gauge the impact of foreign-currency fluctuations on the company's revenue from period to period.*

*Earnings per share, gross margin, operating margin, and income tax rate, each excluding restructuring and impairment charges and/or tax method changes, also are non-GAAP financial measures. Restructuring and impairment charges and tax method changes are not part of the ongoing operations of our underlying business. The company believes that these non-GAAP financial measures are useful to investors, lenders and analysts because removing the impact of restructuring and impairment charges and tax method changes facilitates period-to-period comparisons of the company's performance. Please see the reconciliations of these items to our earnings per share and other income (expense) calculated under GAAP, below.*

The following table sets forth revenue for the three-month periods ended December 31, 2022 and 2021 for each of our reportable segments (U.S. dollars in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended**<br> **December 31,** | **Three Months Ended**<br> **December 31,** | | |
|  | **2022** | **2021** |<br>**Change** | **Constant-<br> Currency**<br>**Change** |
| *Nu Skin* |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Americas | $128921 | $144000 | (10)% | (7)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mainland China | 73935 | 130708 | (43)% | (37)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia/Pacific | 76606 | 90313 | (15)% | (8)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Korea | 60029 | 92528 | (35)% | (26)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan | 53877 | 63215 | (15)% | 6% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EMEA | 55337 | 68066 | (19)% | (9)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hong Kong/Taiwan | 39789 | 47816 | (17)% | (10)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nu Skin other | 1525 | 156 | 878% | 876% |
| *Total Nu Skin* | 490019 | 636802 | (23)% | (15)% |
| *Rhyz Investments* |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Manufacturing | 29560 | 36360 | (19)% | (19)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rhyz other | 2761 | 274 | 908% | 908% |
| *Total Rhyz Investments* | 32321 | 36634 | (12)% | (12)% |
| &nbsp;&nbsp;&nbsp; Total | $522340 | $673436 | (22)% | (15)% |

---

------

*Nu Skin Enterprises Reports Fourth Quarter and 2022 Financial Results* *page 6*

The following table sets forth revenue for the years ended December 31, 2022 and 2021 for each of our reportable segments (U.S. dollars in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Year Ended**<br> **December 31,** | **Year Ended**<br> **December 31,** | | |
|  | **2022** | **2021** |<br>**Change** | **Constant-**<br> **Currency**<br>**Change** |
| *Nu Skin* |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Americas | $508537 | $547755 | (7)% | (5)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mainland China | 360389 | 568774 | (37)% | (35)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia/Pacific | 344411 | 336651 | 2% | 7% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Korea | 268707 | 354252 | (24)% | (15)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan | 224896 | 266216 | (16)% |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EMEA | 204275 | 283200 | (28)% | (19)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hong Kong/Taiwan | 157197 | 162611 | (3)% | 1% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nu Skin other | 3959 | 3653 | 8% | 8% |
| *Total Nu Skin* | 2072371 | 2523112 | (18)% | (12)% |
| *Rhyz Investments* |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Manufacturing | 149458 | 172120 | (13)% | (13)% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rhyz other | 3830 | 437 | 776% | 776% |
| *Total Rhyz Investments* | 153288 | 172557 | (11)% | (11)% |
| &nbsp;&nbsp;&nbsp; Total | $2225659 | $2695669 | (17)% | (12)% |

---

The following table provides information concerning the number of Customers, Paid Affiliates and Sales Leaders in our core Nu Skin business for the three-month periods ended December 31, 2022 and 2021:

---

| | | | |
|:---|:---|:---|:---|
|  | **Three Months Ended**<br> **December 31,** | **Three Months Ended**<br> **December 31,** | |
| **Customers** | **2022** | **2021** | **Change** |
| &nbsp;&nbsp;&nbsp; Americas | 299287 | 336564 | (11)% |
| &nbsp;&nbsp;&nbsp; Mainland China | 202933 | 315418 | (36)% |
| &nbsp;&nbsp;&nbsp; Southeast Asia/Pacific | 141183 | 169601 | (17)% |
| &nbsp;&nbsp;&nbsp; South Korea | 123749 | 146354 | (15)% |
| &nbsp;&nbsp;&nbsp; Japan | 119152 | 122813 | (3)% |
| &nbsp;&nbsp;&nbsp; EMEA | 197917 | 210414 | (6)% |
| &nbsp;&nbsp;&nbsp; Hong Kong/Taiwan | 62903 | 66395 | (5)% |
| Total | 1147124 | 1367559 | (16)% |

---

---

| | | | |
|:---|:---|:---|:---|
|  | **Three Months Ended**<br> **December 31,** | **Three Months Ended**<br> **December 31,** | |
|  **Paid Affiliates** | **2022** | **2021** | **Change** |
| &nbsp;&nbsp;&nbsp; Americas | 42633 | 49328 | (14)% |
| &nbsp;&nbsp;&nbsp; Mainland China | 23436 | 30546 | (23)% |
| &nbsp;&nbsp;&nbsp; Southeast Asia/Pacific | 38653 | 44050 | (12)% |
| &nbsp;&nbsp;&nbsp; South Korea | 45058 | 52036 | (13)% |
| &nbsp;&nbsp;&nbsp; Japan | 38021 | 38428 | (1)% |
| &nbsp;&nbsp;&nbsp; EMEA | 31869 | 36482 | (13)% |
| &nbsp;&nbsp;&nbsp; Hong Kong/Taiwan | 17286 | 20155 | (14)% |
| Total | 236956 | 271025 | (13)% |

---

------

*Nu Skin Enterprises Reports Fourth Quarter and 2022 Financial Results* *page 7*

---

| | | | |
|:---|:---|:---|:---|
|  | **Three Months Ended**<br> **December 31,** | **Three Months Ended**<br> **December 31,** | |
|  **Sales Leaders** | **2022** | **2021** | **Change** |
| &nbsp;&nbsp;&nbsp; Americas | 9594 | 10879 | (12)% |
| &nbsp;&nbsp;&nbsp; Mainland China<sup>(1)</sup> | 12359 | 18207 | (32)% |
| &nbsp;&nbsp;&nbsp; Southeast Asia/Pacific | 6999 | 8800 | (20)% |
| &nbsp;&nbsp;&nbsp; South Korea | 6094 | 8224 | (26)% |
| &nbsp;&nbsp;&nbsp; Japan | 5936 | 5864 | 1% |
| &nbsp;&nbsp;&nbsp; EMEA | 4740 | 5743 | (17)% |
| &nbsp;&nbsp;&nbsp; Hong Kong/Taiwan | 3015 | 3666 | (18)% |
| Total | 48737 | 61383 | (21)% |

---

(1) The December 31, 2022 number reflects a modified Sales Leader definition, as described in our annual report on form 10-K.

● "Customers" are persons who have purchased directly from the Company during the three months ended as of the date indicated. Our Customer numbers include members of our sales force who made such a purchase, including Paid Affiliates and those who qualify as Sales Leaders, but they do not include consumers who purchase directly from members of our sales force.

● "Paid Affiliates" are any Brand Affiliates, as well as members of our sales force in Mainland China, who earned sales compensation during the three-month period. In all of our markets besides Mainland China, we refer to members of our independent sales force as "Brand Affiliates" because their primary role is to promote our brand and products through their personal social networks.

<br> ● "Sales Leaders" are the three-month average of our monthly Brand Affiliates, as well as sales employees and independent marketers in Mainland China, who achieved certain qualification requirements as of the end of each month of the quarter.

#### NU SKIN ENTERPRISES, INC.

#### Consolidated Statements of Income (Unaudited)
(U.S. dollars in thousands, except per share amounts)

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended**<br> **December 31,** | **Three Months Ended**<br> **December 31,** | **Year Ended**<br> **December 31,** | **Year Ended**<br> **December 31,** |
|  | **2022** | **2021** | **2022** | **2021** |
| Revenue | $522340 | $673436 | $2225659 | $2695669 |
| Cost of sales | 147816 | 173775 | 630915 | 675223 |
| Gross profit | 374524 | 499661 | 1594744 | 2020446 |
| Operating expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp; Selling expenses | 201031 | 263265 | 879634 | 1080153 |
| &nbsp;&nbsp;&nbsp; General and administrative expenses | 127664 | 164206 | 555769 | 654431 |
| &nbsp;&nbsp;&nbsp; Restructuring and impairment expenses | 18370 | 51870 | 48494 | 51870 |
| Total operating expenses | 347065 | 479341 | 1483897 | 1786454 |
| Operating income (loss) | 27459 | 20320 | 110847 | 233992 |
| Other income (expense), net | (3104) | (1884) | (21877) | (1533) |
| Income before provision for income taxes | 24355 | 18436 | 88970 | 232459 |
| Provision (benefit) for income taxes | (32860) | 27666 | (15808) | 85193 |
| Net income (loss) | $57215 | $(9230) | $104778 | $147266 |
| Net income (loss) per share: |  |  |  |  |
| &nbsp;&nbsp;&nbsp; Basic | $1.16 | $(0.19) | $2.10 | $2.93 |
| &nbsp;&nbsp;&nbsp; Diluted | $1.15 | $(0.18) | $2.07 | $2.86 |
| Weighted-average common shares outstanding (000s): |  |  |  |  |
| &nbsp;&nbsp;&nbsp; Basic | 49452 | 49862 | 50002 | 50193 |
| &nbsp;&nbsp;&nbsp; Diluted | 49783 | 50801 | 50525 | 51427 |

---

------

*Nu Skin Enterprises Reports Fourth Quarter and 2022 Financial Results* *page 8*

#### NU SKIN ENTERPRISES, INC.

#### Consolidated Balance Sheets (Unaudited)
(U.S. dollars in thousands)

---

| | | |
|:---|:---|:---|
|  | **December 31,**<br> **2022** | **December 31,**<br> **2021** |
|  **ASSETS** | | |
|  Current assets: |  |  |
| &nbsp;&nbsp;&nbsp; Cash and cash equivalents | $264725 | $339593 |
| &nbsp;&nbsp;&nbsp; Current investments | 13784 | 15221 |
| &nbsp;&nbsp;&nbsp; Accounts receivable, net | 47360 | 41299 |
| &nbsp;&nbsp;&nbsp; Inventories, net | 346183 | 399931 |
| &nbsp;&nbsp;&nbsp; Prepaid expenses and other | 87816 | 76906 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total current assets | 759868 | 872950 |
|  Property and equipment, net | 444806 | 453674 |
|  Operating lease right-of-use assets | 98734 | 120973 |
|  Goodwill | 206432 | 206432 |
|  Other intangible assets, net | 66701 | 76991 |
|  Other assets | 244429 | 175460 |
|  Total assets | $1820970 | $1906480 |
|  **LIABILITIES AND STOCKHOLDERS' EQUITY** |  |  |
|  Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp; Accounts payable | $53963 | $49993 |
| &nbsp;&nbsp;&nbsp; Accrued expenses | 280280 | 372201 |
| &nbsp;&nbsp;&nbsp; Current portion of long-term debt | 25000 | 107500 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total current liabilities | 359243 | 529694 |
|  Operating lease liabilities | 76540 | 88759 |
|  Long-term debt | 377466 | 268781 |
|  Other liabilities | 110425 | 106474 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total liabilities | 923674 | 993708 |
|  Commitments and contingencies |  |  |
|  Stockholders' equity: |  |  |
| &nbsp;&nbsp;&nbsp; Class A common stock – 500 million shares authorized, $0.001 par value, 90.6 million shares issued | 91 | 91 |
| &nbsp;&nbsp;&nbsp; Additional paid-in capital | 613278 | 601703 |
| &nbsp;&nbsp;&nbsp; Treasury stock, at cost – 41.1 million and 40.7 million shares | (1569061) | (1526860) |
| &nbsp;&nbsp;&nbsp; Accumulated other comprehensive loss | (86509) | (73896) |
| &nbsp;&nbsp;&nbsp; Retained earnings | 1939497 | 1911734 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total stockholders' equity | 897296 | 912772 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Total liabilities and stockholders' equity | $1820970 | $1906480 |

---

------

*Nu Skin Enterprises Reports Fourth Quarter and 2022 Financial Results* *page 9*

#### NU SKIN ENTERPRISES, INC.

#### Reconciliation of Gross Margin Excluding Impact of Restructuring and Impairment to GAAP Gross Margin
(in thousands, except for per share amounts)

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended**<br> **December 31,** | **Three months ended**<br> **December 31,** | **Year ended**<br> **December 31,** | **Year ended**<br> **December 31,** |
|  | **2022** | **2021** | **2022** | **2021** |
| Gross profit | $374524 | $499661 | $1594744 | $2020446 |
| Impact of restructuring and impairment: |  |  |  |  |
| &nbsp;&nbsp;&nbsp; Inventory write-off | - | 6656 | 26905 | 6656 |
| Adjusted gross profit | $374524 | $506317 | $1621649 | $2027102 |
| Gross margin | 71.7% | 74.2% | 71.7% | 75.0% |
| Gross margin, excluding restructuring impact | 71.7% | 75.2% | 72.9% | 75.2% |
| Revenue | $522340 | $673436 | $2225659 | $2695669 |

---

#### NU SKIN ENTERPRISES, INC.

#### Reconciliation of Operating Margin Excluding Impact of Restructuring and Impairment to GAAP Operating Margin
(in thousands, except for per share amounts)

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended**<br> **December 31,** | **Three months ended**<br> **December 31,** | **Year ended**<br> **December 31,** | **Year ended**<br> **December 31,** |
|  | **2022** | **2021** | **2022** | **2021** |
|  Operating Income | $27459 | $20320 | $110847 | $233992 |
|  Impact of restructuring and impairment: |  |  |  |  |
| &nbsp;&nbsp;&nbsp; Restructuring and impairment | 18369 | 51870 | 48493 | 51870 |
| &nbsp;&nbsp;&nbsp; Inventory write-off | - | 6656 | 26905 | 6656 |
|  Adjusted operating income | $45828 | $78846 | $186245 | $292518 |
|  Operating margin | 5.3% | 3.0% | 5.0% | 8.7% |
|  Operating margin, excluding restructuring impact | 8.8% | 11.7% | 8.4% | 10.9% |
|  Revenue | $522340 | $673436 | $2225659 | $2695669 |

---

------

*Nu Skin Enterprises Reports Fourth Quarter and 2022 Financial Results* *page 10*

#### NU SKIN ENTERPRISES, INC.

#### Reconciliation of Effective Tax Rate Excluding Impact of Restructuring to GAAP Effective Tax Rate
(in thousands, except for per share amounts)

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended**<br> **December 31,** | **Three months ended**<br> **December 31,** | **Year ended**<br> **December 31,** | **Year ended**<br> **December 31,** |
|  | **2022** | **2021** | **2022** | **2021** |
| Provision (benefit) for income taxes | $(32860) | $27666 | $(15808) | $85193 |
| Impact of restructuring on provision for income taxes | (903) | (6933) | 10651 | (6933) |
| Impact of Tax Changes | 32187 | - | 32187 | - |
| Provision for income taxes, excluding impact of restructuring | $(1576) | $20733 | $27030 | $78260 |
| Income before provision for income taxes | 24355 | 18436 | 88970 | 232459 |
| Impact of restructuring and impairment expense: |  |  |  |  |
| &nbsp;&nbsp;&nbsp; Inventory write-off | - | 6656 | 26905 | 6656 |
| &nbsp;&nbsp;&nbsp; Restructuring and impairment | 18369 | 51870 | 48493 | 51870 |
| Impact of charges associated with our Q4 exit from Grow Tech: |  |  |  |  |
| &nbsp;&nbsp;&nbsp; Unrealized investment loss | - | - | 9009 | - |
| Income before provision for income taxes, excluding impact of restructuring | $42724 | $76962 | $173377 | $290985 |
| Effective tax rate | -134.9% | 150.1% | -17.8% | 36.6% |
| Effective tax rate, excluding restructuring impact | -3.7% | 26.9% | 15.6% | 26.9% |

---

------

*Nu Skin Enterprises Reports Fourth Quarter and 2022 Financial Results* *page 11*

#### NU SKIN ENTERPRISES, INC.

#### Reconciliation of Earnings Per Share Excluding Impact of Restructuring to GAAP Earnings Per Share
(in thousands, except for per share amounts)

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended**<br> **December 31,** | **Three months ended**<br> **December 31,** | **Year ended**<br> **December 31,** | **Year ended**<br> **December 31,** |
|  | **2022** | **2021** | **2022** | **2021** |
|  Net income | $57215 | $(9230) | $104778 | $147266 |
|  Impact of restructuring and impairment expense: |  |  |  |  |
| &nbsp;&nbsp;&nbsp; Restructuring and impairment | 18369 | 51870 | 48493 | 51870 |
| &nbsp;&nbsp;&nbsp; Cost of sales - Restructuring | - | 6656 | 26905 | 6656 |
| &nbsp;&nbsp;&nbsp; Tax impact | 903 | 6933 | (9566) | 6933 |
|  Impact of charges associated with our Q4 exit from Grow Tech: |  |  |  |  |
| &nbsp;&nbsp;&nbsp; Unrealized loss on investment | - | - | 9009 | - |
| &nbsp;&nbsp;&nbsp; Tax impact | - | - | (1085) | - |
|  Tax impact from method change | (32187) | - | (32187) | - |
|  Adjusted net income | $44300 | $56229 | $146347 | $212725 |
|  Diluted earnings per share | $1.15 | $(0.18) | $2.07 | $2.86 |
|  Diluted earnings per share, excluding restructuring impact | $0.89 | $1.11 | $2.90 | $4.14 |
|  Weighted-average common shares outstanding (000): | 49783 | 50801 | 50525 | 51427 |

---

------

*Nu Skin Enterprises Reports Fourth Quarter and 2022 Financial Results* *page 12*

#### NU SKIN ENTERPRISES, INC.

#### Reconciliation of Earnings Per Share Excluding Impact of Restructuring to GAAP Earnings Per Share

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended**<br> **March 31,** | **Three months ended**<br> **March 31,** | **Year ended December 31,** | **Year ended December 31,** |
|  | **2023 - Low-**<br> **end** | **2023 High-**<br> **end** | **2023 - Low-**<br> **end** | **2023 High-**<br> **end** |
|  Earnings Per Share | $0.17 | $0.27 | $2.27 | $2.67 |
|  Impact of restructuring and impairment expense: |  |  |  |  |
| &nbsp;&nbsp;&nbsp; Restructuring and impairment | 0.10 | 0.10 | 0.10 | 0.10 |
| &nbsp;&nbsp;&nbsp; Tax impact | (0.02) | (0.02) | (0.02) | (0.02) |
|  Adjusted EPS | $0.25 | $0.35 | $2.35 | $2.75 |

---

\# \# \#

#### CONTACTS:
Media: <u>media@nuskin.com</u>, (801) 345-6397

Investors: <u>investorrelations@nuskin.com</u>, (801) 345-3577

------